Mohan C. Thakuri

1.4k total citations · 1 hit paper
9 papers, 932 citations indexed

About

Mohan C. Thakuri is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Mohan C. Thakuri has authored 9 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Hematology and 2 papers in Genetics. Recurrent topics in Mohan C. Thakuri's work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (3 papers) and Trace Elements in Health (2 papers). Mohan C. Thakuri is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (3 papers) and Trace Elements in Health (2 papers). Mohan C. Thakuri collaborates with scholars based in United States and Argentina. Mohan C. Thakuri's co-authors include Antje Hoering, Bart Barlogie, Brian G.M. Durie, S. Vincent Rajkumar, Joshua Epstein, Christopher M. Reynolds, Angela Dispenzieri, Robert Z. Orlowski, Frederic J. Reu and Rachael Sexton and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Mohan C. Thakuri

9 papers receiving 910 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

2016 594 citations Brian G.M. Durie, Antje Hoering et al. The Lancet profile →

Peers

Countries citing papers authored by Mohan C. Thakuri

Since Specialization

Citations

This map shows the geographic impact of Mohan C. Thakuri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohan C. Thakuri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohan C. Thakuri more than expected).

Fields of papers citing papers by Mohan C. Thakuri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohan C. Thakuri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohan C. Thakuri. The network helps show where Mohan C. Thakuri may publish in the future.

Co-authorship network of co-authors of Mohan C. Thakuri

This figure shows the co-authorship network connecting the top 25 collaborators of Mohan C. Thakuri. A scholar is included among the top collaborators of Mohan C. Thakuri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohan C. Thakuri. Mohan C. Thakuri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance) 2021 ·Blood Advances ·Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, (unknown), Jonathan E. Kolitz, Mohan C. Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson	23
2	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) 2020 ·Blood Cancer Journal ·Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar, Angela Dispenzieri, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Robert Z. Orlowski, Bart Barlogie	139
3	Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT) 2018 ·Blood ·Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar, Angela Dispenzieri, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Robert Z. Orlowski, Bart Barlogie	21
4	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial breakdown → 2016 ·The Lancet ·Brian G.M. Durie, Antje Hoering, Muneer H. Abidi, S. Vincent Rajkumar, Joshua Epstein, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Rachael Sexton, Robert Z. Orlowski, Bart Barlogie, Angela Dispenzieri	594
5	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 2015 ·Blood ·Brian G.M. Durie, Antje Hoering, S. Vincent Rajkumar, Muneer H. Abidi, Joshua Epstein, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Rachael Sexton, Robert Z. Orlowski, Bart Barlogie, Angela Dispenzieri	43
6	Copper deficiency causes reversible myelodysplasia 2007 ·American Journal of Hematology ·(unknown), Yi‐Kong Keung, Mohan C. Thakuri, (unknown), David D. Hurd, John D. Owen, István Molnár	59
7	A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old 2007 ·Journal of Clinical Oncology ·Guido Marcucci, Barry Kurt Moser, William Blum, Wendy Stock, Meir Wetzler, Jonathan E. Kolitz, Mohan C. Thakuri, (unknown), Robert K. Stuart, Richard A. Larson	38
8	Copper Deficiency Anemia Is Not Uncommon in a Hematology Practice. 2005 ·Blood ·(unknown), Yi‐Kong Keung, Mohan C. Thakuri, Michael W. Beaty, John D. Owen, István Molnár	1
9	Hantavirus infection in people inhabiting a highly endemic region of the Gran Chaco territory, Paraguay: association with Trypanosoma cruzi infection, epidemiological features and haematological characteristics 2003 ·Annals of Tropical Medicine and Parasitology ·Jorge F. Ferrer, David T. Galligan, E. Esteban, (unknown), (unknown), Silvina Elena Gutiérrez, (unknown), Mohan C. Thakuri, Laurent J. Feldman, Bernard J. Poiesz, Colleen B. Jonsson	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact